Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts

Leukemia

Volumn 28, Issue 2, 2014, Pages 278-288

  Agnusdei, V ^a   Minuzzo, S ^b   Frasson, C ^b   Grassi, A ^a   Axelrod, F ^c   Satyal, S ^c   Gurney, A ^c   Hoey, T ^c   Seganfreddo, E ^b   Basso, G ^b   Valtorta, S ^d   Moresco, R M ^d   Amadori, A ^a,b   Indraccolo, S ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c OncoMed Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

apoptosis; Notch1; predictive biomarkers; T ALL; targeted therapy

Indexed keywords

ANISOMYCIN; CARRIER PROTEIN; CD5 ANTIGEN; CD7 ANTIGEN; CR2 PROTEIN; DEXAMETHASONE; DTX1 PROTEIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; JAGGED1; MONOCLONAL ANTIBODY; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; OMP 52M 51; OMP 52M51; RITUXIMAB; SLC16A6 PROTEIN; SLC1A4 PROTEIN; SLC24A6 PROTEIN; SLC44A1 PROTEIN; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; IMMUNOPHENOTYPING; IN VIVO STUDY; INTERVENTION STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ADOLESCENT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR, NOTCH1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893722687     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.183     Document Type: Article

References (39)

1. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006; 20: 537-539.
2. Weng AP, Ferrando AA, Lee W, Morris 4th JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
3. Dohda T, Maljukova A, Liu L, Heyman M, Grandér D, Brodin D et al. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res 2007; 313: 3141-3152.
4. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266.
5. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 2006; 26: 8022-8031.
6. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109.
7. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
8. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 2008; 9: 377-383.
9. van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11: 496-502.
10. Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 2010; 5: e9094.
11. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-1057.
12. Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011; 25: 588-598.
13. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-233.
14. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613.
15. Castor A, Nilsson L, Astrand-Grundström I, Buitenhuis M, Ramirez C, Anderson K et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-637.
16. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004; 104: 2919-2925.
17. George AA, Franklin J, Kerkof K, Shah AJ, Price M, Tsark E et al. Detection of leukemic cells in the CD34(\+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 2001; 97: 3925-3930.
18. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007; 109: 674-682.
19. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia 2011; 25: 1249-1258.
20. Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010; 116: 5268-5279.
21. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA et al. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One 2012; 7: e39725.
22. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.
23. Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 2011; 118: 1579-1590.
24. Koh HS, Lee C, Lee KS, Ham CS, Seong RH, Kim SS et al. CD7 expression and galectin-1-induced apoptosis of immature thymocytes are directly regulated by NF-kappaB upon T-cell activation. Biochem Biophys Res Commun 2008; 370: 149-153.
25. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-281.
26. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
27. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, Kim H et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007; 14: 209-219.
28. Palomero T, Barnes KC, Real PJ, Glade Bender JL, Sulis ML, Murty VV et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia 2006; 20: 1279-1287.
29. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781-785.
30. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med 2007; 204: 1813-1824.
31. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009; 23: 1374-1377.
32. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004; 5: 247-253.
33. Watanabe N, Murakami J, Kameda K, Kato H, Kamisaki Y, Noguchi K et al. F-18 FDG-PET imaging in adult T-cell leukemia lymphoma. Clin Nucl Med 2008; 33: 423-425.
34. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
35. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
36. Sarmento LM, Barata JT. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev Anticancer Ther 2011; 11: 1403-1415.
37. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
38. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-1106.
39. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119: 1963-1971.